[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 19, 1994

Incorrect Financial Disclosure Statement.

JAMA. 1994;272(15):1170. doi:10.1001/jama.1994.03520150036032

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

—In the Original Contribution entitled "Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome," by Fisher et al, published in the June 15, 1994, issue of The Journal (1994;271:1836-1843), an incorrect financial disclosure statement appeared. In the third footnote on page 1836, Steven M. Opal, MD, is identified as a paid consultant to Synergen Inc, Boulder, Colo, for the development of recombinant human interleukin 1 receptor antagonist. Dr Opal has not entered into a paid consultant's agreement with Synergen Inc, although he has received the standard compensation received by independent site investigators for the study and received by members of the study's Clinical Evaluation Committee.

First Page Preview View Large
First page PDF preview
First page PDF preview
×